Abicipar maintains vision gain in wet AMD with less frequent dosing

Visual gains attained in year 1 of the CEDAR and SEQUOIA trials sustained effectively with four injections of abicipar as with 12 injections of ranibizumab in year 2, according to data from the virtual American Society of Retina Specialists meeting.
Further, mathematical model simulations predicted longer duration of treatment effect.
The CEDAR and SEQUOIA studies demonstrated that abicipar pegol, either at 8-week or 12-week dosing intervals, was noninferior to ranibizumab given monthly in terms of stable visual acuity, and mean change in vision and central retinal thickness, according to Peter

Full Story →